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Background on infl  uenza pandemics
Inﬂ  uenza A virus is one of the most prevalent pathogens, 
causing respiratory illness every winter [1]. Th  ese  inﬂ  u-
enza outbreaks are usually associated with mild symp-
toms, such as fever, headache, sore throat, sneezing and 
nausea, accompanied by decreased activity and food 
intake [2]. Nevertheless, inﬂ  uenza virus still accounts for 
250,000 to 500,000 deaths each year and this number may 
increase due to the recently emerged H1N1 pandemic 
inﬂ  uenza strain [3].
Inﬂ   uenza virus evolves rapidly because of a high 
mutation rate and may escape acquired immunity [4]. 
Th   is antigenic drift is the major reason why outbreaks of 
inﬂ  uenza occur every winter. In addition, the segmented 
genome of inﬂ   uenza virus also increases the risk of 
recom  bination of two or more inﬂ  uenza strains [4]. Th  ese 
major changes in the viral genome, also referred to as 
antigenic shift, could lead to a pandemic outbreak of 
inﬂ  uenza [5]. Although inﬂ  uenza virus itself can lead to 
severe pneumonia, mortality is most often caused by 
complications of the infection or by pre-existing condi-
tions, such as asthma, chronic obstructive pulmo  nary 
disease, pulmonary ﬁ   brosis or cardiovascular disease 
[6-9]. Viruses are well known to cause exacerbations of 
asthma and chronic obstructive pulmonary disease, but 
the association between inﬂ   uenza virus and cardio-
vascular disease is less clear. Nevertheless, epidemio-
logical studies indicate that the incidence of myocardial 
infarction and stroke correlates with the incidence of 
inﬂ   uenza [10], while inﬂ   uenza vaccination has been 
shown to reduce the risk of these cardiovascular events. 
Whether these epidemiological ﬁ   ndings correlate with 
the pro-thrombotic state observed during inﬂ  uenza virus 
infection is still unclear [11].
Epidemiology of secondary bacterial pneumonia
Bacterial superinfection is a common cause of inﬂ  uenza-
related hospitalization of otherwise healthy individuals 
[12]. Primary inﬂ  uenza virus infection may lead to lower 
respiratory tract symptoms, but secondary bacterial 
infections during and shortly after recovery from 
inﬂ  uenza virus infection are a much more common cause 
of pneumonia. Although pandemic strains are usually 
more pathogenic than seasonal inﬂ   uenza strains, the 
excess mortality rates during pandemics is mainly caused 
by secondary bacterial pneumonia [13]. Retrospective 
analysis of post-mortem lung tissue of individuals that 
died from the 1918 pandemic inﬂ  uenza strain indicated 
that most of these people also had a bacterial infection. 
Also, during the inﬂ  uenza pandemic of 1957 more than 
two-thirds of fatal cases were associated with bacterial 
pneumonia [14]. Bacteria such as Staphylococcus aureus
and Haemophilus inﬂ  uenzae  are known to cause 
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is the most prominent pathogen involved [15]. A recent 
report on the new H1N1 inﬂ  uenza strain indicates that 
29% of fatal H1N1 cases between May 2009 and August 
2009 in the United States were associated with a 
secondary bacterial infection [16], which is markedly less 
than for previous inﬂ   uenza pandemics [17,18]. In 
addition to S. aureus and S. pneumoniae, Streptococcus 
pyogenes was also frequently isolated [16,18].  Primary 
infections with these pathogens are usually less severe 
than secondary infections. Th  e incidence of invasive 
pneu  mococcal disease closely correlates with the 
inﬂ  uenza season [19], and pneumococcal vaccination not 
only results in an overall reduced number of pneumonia 
cases, it also leads to markedly reduced cases of virus-
associated pneumonia [20]. Although secondary bacterial 
pneumonia has been described for other respiratory 
viruses as well, the morbidity and mortality is much 
lower than observed for inﬂ  uenza [21,22].
Pathogenesis of bacterial pneumonia with infl  uenza
Bacterial respiratory infection during inﬂ  uenza  virus 
infection can be divided into combined viral/bacterial 
pneumonia or secondary bacterial infection following 
inﬂ  uenza. Clinical symptoms do not distinguish between 
bacterial and viral pneumonia early in the course of 
disease, rendering early clinical distinction a challenge. 
Critically ill patients with viral pneumonia present with 
bilateral interstitial inﬁ   ltrates on the chest radiograph 
indistinguishable from bacterial pneumonia [23]. Other 
markers of inﬂ  ammation are also not speciﬁ  c. Distinction 
between viral and bacterial pneumonia by microbio-
logical and/or molecular techniques, however, is highly 
relevant in terms of initiating antimicrobial therapy, as 
32% of patients with viral pneumonia develop a conco-
mitant bacterial pneumonia [23]. Secondary bacterial 
infections following inﬂ  uenza are more easily recognized 
clinically compared to combined viral/bacterial pneu  monia, 
since these bacterial infections tend to occur during the 
recovery phase from inﬂ   uenza [24]. Epidemio  logical 
studies indicate that individuals infected with inﬂ  uenza 
virus are most susceptible to secondary bacterial 
pneumonia between 4 and 14 days after the onset of 
inﬂ  uenza symptoms [25].
Although the incidence of a secondary bacterial infec-
tion does not show a clear distinction between combined 
viral/bacterial pneumonia and secondary bacterial 
infection following inﬂ   uenza, the processes leading to 
severe bacterial pneumonia in conjunction with inﬂ  uenza 
virus infections are multifactorial and diﬀ  er  between 
early and late bacterial infection. During combined viral/
bacterial infection, the virus not only interacts with the 
host response, it also interacts with bacterial-induced 
inﬂ   ammation, increasing bacterial colonization and 
outgrowth as well as viral replication (Figure  1). 
Conversely, the host response to both patho  gens will 
aﬀ  ect viral replication and bacterial growth [26,27]. From 
a mechanistic point of view, post-inﬂ  uenza pneumonia is 
less complicated than combined viral/bacterial pneu-
monia, since the virus has been cleared (Figure 1). Th  e 
patho  genesis of post-inﬂ   uenza pneumonia involves 
virus-induced changes to the host [28,29]. Th  ese 
diﬀ  erences are important to take into consideration when 
studying the mechanisms of secondary bacterial compli-
ca  tions and may also have an impact on thera  peutic 
strategies to be followed when patients are hospitalized 
for inﬂ  uenza complicated by pneumonia.
Th  e severity of combined viral/bacterial infection or 
post-inﬂ   uenza pneumococcal pneumonia is classically 
attributed to inﬂ   uenza-induced damage to the airway 
epithelium, which leads to increased colonization of 
bacteria at the basal membrane [30]. Inﬂ  uenza  virus 
preferentially infects and replicates in airway epithelial 
cells, leading to the induction of an antiviral process in 
order to eradicate the virus. Besides limiting viral replica-
tion by means of transcriptional and translational 
Figure 1. Complexity of combined viral/bacterial and post-infl  uenza pneumonia. Severe bacterial pneumonia following infl  uenza can be 
subdivided into combined viral/bacterial (left) and post-infl  uenza pneumonia (right). During combined viral/bacterial pneumonia, the virus, the 
bacteria and the host all interact with each other. The severity of post-infl  uenza pneumonia is due to virus-induced changes to the host that aff  ect 
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apoptosis [31]. Th   e apoptotic bodies containing the virus 
are subsequently removed by (alveolar) macrophages 
[32]. Major drawbacks of this antiviral mechanism include 
not only the increased risk of bacterial colonization, but 
also enhanced invasion by bacteria. In addition to 
epithelial injury, mucociliary clearance has recently been 
shown to be impaired during inﬂ  uenza virus infection, 
leading to an enhanced burden of S. pneumoniae already 
at 2 hours after bacterial challenge [33].
Over the past few years it has become increasingly 
clear that epithelial injury is not the only factor that 
contributes to the severe outcome resulting from bac-
terial complications during inﬂ  uenza infection [27-29,  33,   
34]. Mouse studies have revealed additional mechanisms 
that play a critical role in either combined viral/bacterial 
infection or post-inﬂ  uenza  pneumococcal  pneumonia 
(sum  marized in Table 1). Most mouse models that are 
currently used focus on combined viral/bacterial pneu-
monia (bacterial challenges up to 7 days after inﬂ  uenza) 
[25,33-35], while other models are used to investigate 
post-inﬂ   uenza pneumonia [28,29] (bacterial challenges 
ranging from 14 days up to 35 days after inﬂ  uenza 
infection).
Viral factors contributing to secondary bacterial 
complications
Several viral factors have been identiﬁ  ed as critical for 
the development of secondary bacterial pneumonia. Viral 
neuraminidase has been shown to enhance bacterial 
growth as well as bacterial dissemination in a mouse 
model for secondary pneumococcal pneumonia. Studies 
with recombinant inﬂ  uenza strains containing diﬀ  erent 
neuraminidase genes indicate that neuraminidase activity 
correlates with increased adhesion of pneumococci to 
airway epithelial cells, which could be reversed by adding 
neuraminidase inhibitors [36]. Inﬂ   uenza strains with 
relatively high neuraminidase activity, such as the 1957 
pandemic inﬂ   uenza strain, were associated with an 
increased incidence of pneumococcal pneumonia and 
higher mortality rates in mice after bacterial challenge 
[37]. In addition, mice treated with neuraminidase inhibi-
tors for up to 5 days after viral exposure showed markedly 
increased survival rates. Nevertheless, neuraminidase 
inhibitors were only partially protective in this model for 
bacterial complications following inﬂ  uenza virus infec-
tion [38].
In addition to neuraminidase, PB1-F2, a pro-apoptotic 
protein expressed by most inﬂ  uenza A strains, has been 
implicated in the pathogenesis of secondary bacterial 
pneumonia as well. Mice infected with viral strains 
lacking PB1-F2 were largely protected against secondary 
bacterial complications. In line with this, mice infected 
with a viral strain that expresses the PB1-F2 protein from 
the 1918 pandemic inﬂ  uenza strain appeared to be highly 
susceptible to pneumococcal pneumonia [39]. Since 
PB1-F2 did not have an impact on bacterial loads and 
since it has been implicated in the pathogenesis of 
primary infection with inﬂ   uenza virus, it may be 
concluded that PB1-F2 induces lung pathology during 
viral infection, which may enhance the inﬂ  ammatory 
response to a secondary challenge. Th  e underlying 
mechanism of PB1-F2-induced lung pathology is largely 
unknown.
Table 1. Predisposing factors identifi  ed for combined viral/bacterial pneumonia and/or post-infl  uenza pneumonia
  Factors associated with combined  Factors associated with
 viral/bacterial  infection  post-infl  uenza pneumonia
Viral factors  Viral neuraminidase [37,38]   Not involved, that is, virus is cleared [28,29]
 PB1-F2  [39] 
Bacterial factors  Pneumococcal surface protein A [40]  Unknown
Mechanical factors (host)  Epithelial injury [30]   Unknown
  Mucociliary velocity [33]
Immune cells (host)  Neutrophil function [34,47,49,51,57]  Neutrophil function [28] 
  Neutrophil recruitment [52,53,55]  Neutrophil recruitment [29]
  Neutrophil apoptosis [48,54] 
 Macrophages  [57,58] 
 Monocytes  [57]
Cytokines/chemokines (host)  IFN-γ [59]   IL-10 [28]
 IFN-α/β  [53] 
 KC  [53] 
 MIP-2  [53]
Pattern recognition receptors (host)  MARCO [59]  TLR2 [29] 
   TLR4  [29] 
   TLR5  [29]
Metabolic enzymes (host)  Unknown  Indoleamine 2,3-dioxygenase [61]
Abbreviations: IFN, interferon; IL, interleukin; KC, keratinocyte-derived chemokine; MARCO, macrophage receptor with collagenous structure; MIP, macrophage 
infl  ammatory protein; TLR, Toll-like receptor
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bacterial pneumonia
Bacterial components that contribute to secondary 
bacterial pneumonia have been poorly investigated. In 
contrast to viral neuraminidase, bacterial neuraminidase 
has not been implicated in combined viral/bacterial 
pneumonia or post-inﬂ  uenza pneumonia [34,37,40]. Th  e 
fact that bacterial neuraminidase does not contribute to 
enhanced replication of inﬂ  uenza is most likely due to 
poor enzymatic activity compared to viral neuraminidase 
and the strict sialic acid substrate requirements of 
bacterial neuraminidase.
In contrast, pneumococcal surface protein A (PspA) 
has been shown to increase bacterial colonization in mice 
infected with inﬂ   uenza virus [40]. PspA is known to 
interfere with complement-mediated phagocytosis and 
lactoferrin-mediated killing. However, it is also identiﬁ  ed 
as a virulence factor for primary pneumococcal pneu-
monia [41]. As such, PspA seems to have a limited 
contribution to the severe outcome of bacterial pneu-
monia with inﬂ  uenza. Similarly, pneumococcal hyaluro  ni-
dase has been identiﬁ  ed as a virulence factor for primary 
pneumococcal pneumonia, but did not have an impact on 
pneumococcal pneumonia following inﬂ  uenza [40].
S. pneumoniae has been shown to bind to the platelet-
activating factor receptor (PAFR) through phosphatidyl-
choline in the bacterial cell wall [42], which has been 
suggested to increase colonization of bacteria and/or to 
mediate transition from the lung to the blood [43]. Th  e 
impact of this interaction was further investigated using 
PAFR knockout mice [44,45] and pharmacological inhi-
bitors of PAFR [35]. Although inﬂ  uenza virus has been 
shown to upregulate the expression of PAFR [43], no 
studies have identiﬁ  ed a more pronounced role for it in 
secondary pneumococcal pneumonia compared to 
primary pneumococcal infection [35,44,45]. PAFR 
appears to mediate invasive pneumococcal disease during 
primary and secondary pneumococcal pneumonia, while 
colonization within the lung seems to be dependent on 
the bacterial strain [43-45].
In conclusion, there is little evidence that bacterial 
virulence plays an important role in the pathogenesis of 
secondary pneumococcal pneumonia after inﬂ  uenza. 
Protease activity by S. aureus has been shown to increase 
the virulence of inﬂ  uenza A virus in mice by cleaving 
virus hemagglutinin. However, protease inhibitors have 
not been further investigated in models of secondary 
bacterial pneumonia [46].
Host factors contributing to secondary bacterial 
pneumonia
Most studies on the mechanism underlying bacterial 
pneumonia following inﬂ  uenza have focused on impaired 
host defense against secondary infection with an unrelated 
pathogen. Inﬂ  uenza virus infection has been shown to 
impair neutrophil function at multiple levels [28,34,47-
54]. Initial studies indicated that inﬂ  uenza virus reduces 
chemotaxis and chemokinesis of neutro  phils in vitro and 
in vivo [55], which appeared to be strain-dependent in 
subsequent studies with patients infected with inﬂ  uenza 
virus [52]. In addition to this direct inhibitory 
mechanism, a recent study identiﬁ  ed type I interferon 
(IFN), an antiviral cytokine, as an impor  tant factor in the 
downregulation of relevant chemokines, such as 
keratinocyte-derived chemokine and macrophage 
inﬂ  ammatory protein 2, thereby inhibit  ing the migration 
of neutrophils [53]. However, several studies reported 
increased, rather than reduced, numbers of neutrophils 
after secondary bacterial challenge in mice infected with 
inﬂ   uenza virus [28,34,56]. Th  e increased number of 
neutrophils may correlate with higher bacterial loads in 
these models of secondary bacterial pneumonia. Th  e 
higher bacterial loads might be explained by a reduced 
phagocytic capacity of neutrophils [28,34,45,57,58]. In 
vitro studies with ultraviolet irradiated and heat killed 
inﬂ  uenza virus indicated that the reduction in phagocytic 
capacity is mediated, at least in part, by viral neurami-
nidase activity [58]. Nevertheless, the impaired eﬀ  ector 
function is still present after the virus has been cleared 
[28], indicating that host factors contribute to impaired 
bacterial killing. IL-10 production is synergistically 
enhanced in mice infected with S. pneumoniae during 
viral infection [38,56] as well as after clearance [28] of 
inﬂ  uenza virus. Inhibition of IL-10 markedly improved 
survival in a mouse-model for post-inﬂ  uenza pneumo-
coccal pneumonia, which was associated with reduced 
bacterial loads. Th  e role of IL-10 in combined viral/
bacterial pneumonia seems to be limited, since IL-10 
knockout mice did not show an improved response to 
secondary bacterial infection [59]. It should be noted, 
however, that IL-10 knockout mice respond diﬀ  erently to 
primary viral infection as well, leading to a more 
pronounced proinﬂ  ammatory state [60]. Together, these 
ﬁ  ndings not only illustrate the complexity of secondary 
bacterial pneumonia, they also stress that combined 
viral/bacterial infection is intrinsically diﬀ  erent  from 
post-inﬂ  uenza pneumonia.
Th   e tryptophan-catabolizing enzyme indoleamine 
2,3-dioxygenase (IDO) has been shown to enhance IL-10 
levels in a mouse model for post-inﬂ  uenza pneumococcal 
pneumonia [61]. Inhibition of IDO, which is expressed 
during the recovery phase of inﬂ  uenza infection, reduced 
bacterial loads during secondary, but not primary, 
pneumococcal infection. Despite a clear reduction in 
bacterial loads as well as markedly reduced levels of IL-10 
and TNF-α, it did not have an impact on survival. It is 
unlikely, therefore, that IDO predisposes for bacterial 
pneumonia by means of enhancing IL-10 production. 
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IDO activity induces apoptosis of neutrophils during 
bacterial infection of the airways (submitted for 
publication). IDO-mediated apoptosis, which has been 
extensively studied for T lymphocytes, is particularly 
mediated by metabolites such as kynurenine and 3-hydroxy 
anthranilic acid, rather than depletion of tryptophan. 
Tryptophan metabolites have been implicated in 
monocyte and macrophage apoptosis as well [62,63]. 
Together, these data indicate that IDO functions as a 
natural mechanism to remove inﬂ  ammatory cells. Th  is 
mechanism to resolve inﬂ  ammation prevents excessive 
damage to the airways after viral infection, but increases 
the susceptibility to secondary bacterial pneumonia.
In addition to neutrophils, macrophages and mono-
cytes [58,64] have also been shown to have a reduced 
phagocytic capacity during inﬂ  uenza infection. IFN-γ has 
been shown to play a critical role in macrophage 
dysfunction through downregulation of ‘macrophage 
receptor with collagenous structure’ (MARCO) expres-
sion on alveolar macrophages [65]. MARCO can be 
classiﬁ  ed as a scavenger receptor involved in the innate 
recognition and subsequent killing of bacteria. MARCO 
knockout mice have been shown to be more susceptible 
to pneumococcal pneumonia, which was associated with 
higher bacterial loads, enhanced lung pathology and 
increased mortality rates [63]. Although other factors 
that mediate opsonization or phagocytosis of bacteria 
have been extensively studied for primary bacterial 
pneumonia [66-68], their roles in either combined viral/
bacterial pneumonia or post-inﬂ   uenza pneumonia are 
largely unknown.
Knowledge about the role of other pattern recognition 
receptors, such as Toll-like receptors (TLRs), is limited. A 
recent study indicated that inﬂ   uenza virus infection 
resulted in sustained desensitization of TLRs for up to 
6 weeks after inﬂ  uenza virus infection [29]. Mice exposed 
to inﬂ   uenza virus exert a poor response to lipopoly-
saccharide, lipoteichoic acid and ﬂ   agellin, ligands for 
TLR4, TLR2 and TLR5, respectively, as reﬂ  ected  by 
reduced neutrophil numbers in bronchoalveolar lavage 
ﬂ  uid. Th  ese data are supported by the fact that TLR2 
knockout mice were equally susceptible to secondary 
bacterial pneumonia following inﬂ  uenza virus infection 
compared to wild-type mice [69]. It is worth noting that 
TLR4 can compensate for a defect in TLR2 during 
primary pneumococcal pneumonia [70]. In addition to 
TLR desensitization, CD200R expression has been 
proposed to impair the host response towards bacteria 
during inﬂ  uenza virus infection [71]. Although CD200-
CD200R interactions have been shown to negatively 
regulate inﬂ  ammation through induction of IDO [72], its 
role in secondary bacterial pneumonia has not been 
investigated yet.
Taken together, these host factors contributing to 
severe post-inﬂ   uenza pneumonia all relate to altered 
innate immune mechanisms that are supposed to resolve 
or dampen virus-induced inﬂ   ammation and related 
tissue damage. It should be noted that most studies have 
been performed using mouse models for combined viral/
bacterial pneumonia or post-inﬂ   uenza bacterial pneu-
monia and require conﬁ  rmation in humans.
Current treatment options
Vaccination against inﬂ  uenza has been shown to reduce 
mortality rates during inﬂ  uenza epidemics [73]. Seasonal 
inﬂ   uenza epidemics are primarily caused by antigenic 
drift (that is, single-point mutations that are caused by 
the high mutation rate of inﬂ   uenza virus strains). 
Although single-point mutations occur at random, 
genetic changes can be predicted in advance [74]. Th  ese 
predictions provide the opportunity to develop vaccines 
to prevent seasonal inﬂ  uenza and therefore also the risk 
of secondary bacterial infections. Vaccination of elderly 
patients has been shown to reduce hospitalizations by 
52%. In contrast to seasonal inﬂ  uenza, pandemic inﬂ  u-
enza, such as caused by the recently emerged H1N1 
strain [3,75], results from antigenic shift. It is hard to 
predict when these changes occur and which strains are 
involved. It is virtually impossible, therefore, to develop 
vaccines directed against pandemic inﬂ  uenza strains in 
advance. Vaccines against new inﬂ   uenza strains only 
become available when the vaccine has been validated 
extensively.
Besides vaccination, treatment options to prevent a 
complicated course of inﬂ   uenza is to inhibit viral 
replication with antiviral agents, such as amantadine 
(Symmetrel®), or neuraminidase inhibitors, such as 
oseltamivir (Tamiﬂ   u®) and zanamivir (Relenza®). Th  ese 
agents have been shown to reduce inﬂ  uenza-related 
symptoms [76-78], but their eﬃ   cacy  against  bacterial 
complications remains to be determined [79]. Viral 
neuraminidase has been shown to be involved in the 
enhanced response to bacteria in a mouse model for 
post-inﬂ  uenza pneumococcal pneumonia [37]. Moreover, 
mice treated with neuraminidase inhibitors were less 
susceptible to secondary bacterial infections. However, 
neuraminidase inhibitors did not completely prevent 
mortality in mice with inﬂ  uenza complicated by bacterial 
pneumonia, which may relate to the relatively small time-
window in which neuraminidase inhibitors can reduce 
viral replication [80]. In addition, the eﬃ   cacy  of 
neuraminidase inhibitors in established viral/bacterial 
pneumonia was not tested. Rimantadine, an amantadine 
analogue, did not improve mortality in mice with post-
inﬂ  uenza pneumococcal pneumonia [33]. Th  e  eﬃ   cacy of 
these inhibitors in the treatment of bacterial compli  ca-
tions in humans has not been established yet. Th  ese 
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bacterial pneumonia.
Patients with community-acquired pneumonia who 
demonstrate or have demonstrated signs and symptoms 
of illness compatible with inﬂ  uenza in the days or weeks 
before should be empirically treated with antibiotics 
targeting S. pneumoniae and S. aureus in order to cover 
the most common pathogens causing the most severe 
secondary infections, and coverage of H. inﬂ  uenzae is 
also recommended [81]. Appropriate antimicrobial 
agents therefore include cefotaxime, ceftriaxone and 
respira tory  ﬂ  uoroquinolones. As mentioned above, com-
bined infection needs to be conﬁ  rmed by microbiological 
and molecular techniques. When samples from 
respiratory tract are proven culture negative, antibiotics 
can be stopped. Treatment targeted at methicillin-
resistant S. aureus (by vancomycin or linezolid) should be 
limited to patients with conﬁ   rmed infection or a 
compatible clinical presentation (shock and necrotizing 
pneumonia) [80]. Of note, mouse studies indicate that 
ampicillin treatment is insuﬃ   cient to prevent mortality 
in a model for secondary bacterial pneumonia, while the 
bacteriostatic protein synthesis inhibitors clindamycin or 
azithromycin improve the outcome after streptococcal 
pneumonia in inﬂ   uenza-infected mice [82]. Th  is 
protective eﬀ  ect is likely mediated by inhibition of toxin 
release [82], but it may be associated with the anti-
inﬂ   ammatory properties of these latter antimicrobial 
agents as well [83,84]. Although ampicillin alone did not 
have an impact on survival in inﬂ  uenza-infected mice 
with secondary pneumococcal pneumonia, it did 
improve mortality rates in mice previously treated with 
oseltamivir compared to mice treated with oseltamivir 
alone [37].
Future perspectives
Secondary bacterial complications are the result of an 
altered host response due to inﬂ  uenza virus infection. 
Most factors that have been identiﬁ  ed to play a critical 
role in post-inﬂ  uenza pneumococcal pneumonia are in 
fact mechanisms to prevent excessive inﬂ  ammation and/
or to promote resolution of inﬂ   ammation, which are 
initiated to restore tissue homeostasis after clearance of 
the primary infection. At the same time, these mecha-
nisms greatly impair the host response towards secon-
dary unrelated pathogens. Cytokines and chemokines 
appear to play a critical role in dampening virus-induced 
immunopathology. IFN-γ and IL-10 have been shown to 
alter macrophage and neutrophil function, respectively, 
while type I IFN seems to impair neutrophil recruitment 
after secondary bacterial infection. In addition, IDO 
expression is induced by proinﬂ  ammatory cytokines such 
as TNF-α, IFN-γ, IL-12 and IL-18, leading to apoptosis of 
inﬂ  ammatory cells. Although the contribution of these 
mediators needs to be conﬁ  rmed in humans, targeting 
cytokines may be an alternative approach to trigger an 
eﬀ   ective host response to bacteria. Although it is 
practically not feasible to neutralize these inﬂ  ammatory 
mediators as prophylactic treatment to prevent secon-
dary bacterial pneumonia in all inﬂ  uenza-infected 
subjects, it may be a useful approach in hospitalized 
subjects, especially those that are admitted to the 
intensive care unit.
Conclusion
Inﬂ  uenza may be complicated by bacterial pneumonia. It 
is important to consider the time interval between viral 
and bacterial infection. At present, antibiotic treatment 
appears to be the only therapeutic option for post-
inﬂ  uenza pneumonia. Further insight into the underlying 
mechanisms in combined viral/bacterial infection and 
post-inﬂ  uenza pneumonia may provide new targets for 
the treatment of these complicated infections.
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